Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

NCT02222363 is registered in ClinicalTrials.gov with Vivolux AB as lead sponsor.

NCT NCT02222363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02222363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
Lead sponsor
Vivolux AB
Phase
Phase 1
Overall status
Terminated
Start date
February 18, 2015
Completion date
December 28, 2016
Enrollment
19 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

refractory cancer